Taro Pharmaceutical Industries is a drug manufacturers - specialty & generic business based in the US. Taro Pharmaceutical Industries shares (TARO) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $32.67 - $45.76 |
| 50-day moving average | $42.53 |
| 200-day moving average | $40.34 |
| Wall St. target price | $43.00 |
| PE ratio | 30.049 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.43 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2024-07-10
| 1 week (2024-10-06) | N/A |
|---|---|
| 1 month (2024-09-13) | N/A |
| 3 months (2024-07-13) | N/A |
| 6 months (2024-04-17) | -100.00% |
| 1 year (2023-10-17) | -100.00% |
|---|---|
| 2 years (2022-10-17) | -100.00% |
| 3 years (2021-10-15) | 63.83 |
| 5 years (2019-10-17) | 76.03 |
Valuing Taro Pharmaceutical Industries stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Taro Pharmaceutical Industries's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Taro Pharmaceutical Industries's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Taro Pharmaceutical Industries shares trade at around 30x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Taro Pharmaceutical Industries's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $38.4 million.
The EBITDA is a measure of a Taro Pharmaceutical Industries's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $629.2 million |
|---|---|
| Operating margin TTM | 5.93% |
| Gross profit TTM | $293.1 million |
| Return on assets TTM | 0.21% |
| Return on equity TTM | 3.06% |
| Profit margin | 8.56% |
| Book value | $47.71 |
| Market Capitalization | $1.6 billion |
TTM: trailing 12 months
We're not expecting Taro Pharmaceutical Industries to pay a dividend over the next 12 months.
Taro Pharmaceutical Industries's shares were split on a 2:1 basis on 26 July 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Taro Pharmaceutical Industries shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Taro Pharmaceutical Industries shares which in turn could have impacted Taro Pharmaceutical Industries's share price.
Over the last 12 months, Taro Pharmaceutical Industries's shares have ranged in value from as little as $32.67 up to $45.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Taro Pharmaceutical Industries's is 0.557. This would suggest that Taro Pharmaceutical Industries's shares are less volatile than average (for this exchange).
Taro Pharmaceutical Industries Ltd. , a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.